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Background
Mevalonate Kinase Deficiency (MKD) is one of the
autoinflammatory fever syndromes, caused by mutations
in the MKD gene. Systemic inflammatory symptoms
may be mild to severe leading to early death, and recur-
rent bacterial infections frequently develop in the dis-
ease course. On demand NSAID and steroids are the
most commonly used. Few case-reports suggested that
interleukin-1 (IL-1) antagonists could alleviate MKD
symptoms.
Aim
We describe efficacy and safety of IL-1 targeting drugs,
anakinra and canakinumab, in seven children with
MKD.
Methods
A questionnaire containing items of disease activity was
sent to French pediatric and adult rheumatologists. We
collected information from 7 MKD patients treated with
IL-1 antagonists. MKD was suspected clinically then
confirmed genetically in all cases.
Results
The use of IL-1 antagonists was beneficial to all patients
on a long term. Anakinra was daily administered and
canakinumab every 8 weeks, with dose adjustments. The
median clinical score based on fever and symptoms dur-
ing MKD crisis before and after treatment was 9 and 0,5
respectively. The number of days of fever during crisis
before and after treatment was 5,25 and 1,75 respec-
tively. These treatments alleviated biological inflamma-
t o r ym a r k e r s .T h es i d ee f f e c t sw i t ha n a k i n r aw e r el o c a l
pain, inflammatory signs at the injection site, infections
(bacterial pneumopathy and rhinopharyngitis) and acne.
There was no side effect with canakinumab. Three
patients switched from anakinra to canakinumab.
Conclusion
IL-1 targeting drugs appear effective and safe in our
MKD patients. Controlled trials to further assess their
clinical benefit and safety in MKD patients seem
necessary.
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